National Institute of Allergy and Infectious Diseases (NIAID): Cytomegalovirus Retinitis trials

The registry lists 21 Cytomegalovirus Retinitis studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 6Phase 3 2Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) InfectionCompletedNCT00005572
• A Study of Ganciclovir in the Treatment of Cytomegalovirus of the EyesCompletedNCT00001062Phase 1
• Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDSCompletedNCT00001061Phase 2
• The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIVCompletedNCT00001034Phase 2
• The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDSCompletedNCT00000989Not applicable
• A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With GanciclovirCompletedNCT00000970Phase 1
• A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV TherapyCompletedNCT00000905
• Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV RetinitisCompletedNCT00000894Phase 4
• A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) DiseaseWithdrawnNCT00000881Phase 1
• A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)CompletedNCT00000836Phase 2
• HPMPC (Cidofovir) Peripheral CMV Retinitis Trial ProtocolCompletedNCT00000799Not applicable
• CMV Retinitis Retreatment TrialCompletedNCT00000766Phase 2
• Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency SyndromeCompletedNCT00000726Phase 1
• A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV RetinitisCompletedNCT00000698Phase 3
• A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use GanciclovirWithdrawnNCT00000697Phase 2
• Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDSCompletedNCT00000693Not applicable
• A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment FailureCompletedNCT00000691Phase 2
• A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDSCompletedNCT00000688Phase 3
• A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic TherapyCompletedNCT00000673Phase 1
• A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral GanciclovirCompletedNCT00000668Phase 1
• Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir ComponentCompletedNCT00000665Not applicable